On August 2, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, reported that the company’s management team will be participating in one-on-one meetings at the upcoming BTIG Biotechnology Conference, which is taking place both virtually and at the St. Regis New York Hotel in New York City, August 8-9, 2022 (Press release, DiaMedica, AUG 2, 2022, View Source [SID1234617286]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For those interested in meeting with DiaMedica at the conference, please reach out to your BTIG representative to schedule a meeting.